Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,market,shortName,esgPopulated,tradeable,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchangeDataDelayedBy,priceHint,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,longName,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,INSM,199714000,114992000,26849000,,-91402000,,-91641000,51550000,-4171000,-83833000,-83833000,,-7559000,,,,239000,40214000,124047000,44385000,-7569000,,-91641000,-91641000,1922000,2122743000,490755000,201636000,46076000,140000,692391000,1033000,-1922230000,9298000,90000,92438000,409751000,81397000,90000,97027000,501004000,17628000,361575000,52060000,22422000,-20273000,-1181000,-258000,6703000,-37468000,6961000,-123005000,-246000,-128281000,2708000,-2754000,-1066000,15743000,-1181000,419607000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Insmed, Inc.",False,False,NMS,29.13,1630526402,1.0899982,28.32,29.13,28.13,1003452,PRE,0,2,3.8872976,28.13 - 29.13,28.04,0.0,0.0,18,13,finmb_29978,Insmed Incorporated,NasdaqGS,USD,777817,689285,7.129999,0.32409087,22.0 - 45.44,-16.31,-0.35893485,22.0,45.44,1620304200,1635337800,1635769800,-3.165,-2.58,-3.56,-8.182584,1.952,25.024,4.105999,0.16408244,30.25913,-1.1291313,-0.03731539,3349716736,-11.290698,14.923155,15,America/New_York,EDT,-14400000,2.26,,,45.44,22.0,25.02,30.26,777.82k,689.28k,114.99M,,97.34M,1.32%,95.70%,8.11M,10.86,8.88%,7.05%,8.16M,,,,,,0.00%,,,1:10,"Mar 02, 2011","Dec 30, 2020","Mar 30, 2021",-190.36%,-172.09%,-26.36%,-156.42%,167.77M,1.66,9.10%,33.86M,-279.5M,-319.37M,-3.16,,409.75M,3.96,407.6M,202.15,6.16,1.95,-289.69M,-143.26M,Value,08807-1704,Healthcare,521,6,3,"Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",Bridgewater,908 977 9900,NJ,9,1609372800,1625097600,3,United States,http://www.insmed.com,86400,6,700 US Highway 202/206,Biotechnology
t-1,INSM,273912000,114992000,-22864000,,-101592000,,-102213000,56019000,-60125000,-94538000,-94538000,,-7499000,,,,621000,41415000,135953000,101540000,-7054000,,-102213000,-102213000,1972000,2105252000,520271000,275884000,47289000,364000,796155000,1028000,-1830589000,9178000,193000,74058000,532756000,118807000,193000,97233000,622892000,16562000,356318000,49592000,42853000,20705000,-1515000,-167000,12011000,3567000,12178000,-55997000,299000,-66792000,2633000,-6064000,-1366000,9543000,-933000,504085000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Insmed, Inc.",False,False,NMS,29.13,1630526402,1.0899982,28.32,29.13,28.13,1003452,PRE,0,2,3.8872976,28.13 - 29.13,28.04,0.0,0.0,18,13,finmb_29978,Insmed Incorporated,NasdaqGS,USD,777817,689285,7.129999,0.32409087,22.0 - 45.44,-16.31,-0.35893485,22.0,45.44,1620304200,1635337800,1635769800,-3.165,-2.58,-3.56,-8.182584,1.952,25.024,4.105999,0.16408244,30.25913,-1.1291313,-0.03731539,3349716736,-11.290698,14.923155,15,America/New_York,EDT,-14400000,2.26,,,45.44,22.0,25.02,30.26,777.82k,689.28k,114.99M,,97.34M,1.32%,95.70%,8.11M,10.86,8.88%,7.05%,8.16M,,,,,,0.00%,,,1:10,"Mar 02, 2011","Dec 30, 2020","Mar 30, 2021",-190.36%,-172.09%,-26.36%,-156.42%,167.77M,1.66,9.10%,33.86M,-279.5M,-319.37M,-3.16,,409.75M,3.96,407.6M,202.15,6.16,1.95,-289.69M,-143.26M,Value,08807-1704,Healthcare,521,6,3,"Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",Bridgewater,908 977 9900,NJ,9,1609372800,1625097600,3,United States,http://www.insmed.com,86400,6,700 US Highway 202/206,Biotechnology
t-2,INSM,355625000,114992000,41411000,,-63342000,,-63659000,46585000,33021000,-56223000,-56223000,,-7185000,,,,317000,43643000,99866000,10622000,-7119000,,-63659000,-63659000,1436000,2084305000,483654000,357061000,48501000,130000,840715000,1018000,-1728376000,10424000,114000,73708000,588753000,83902000,114000,98422000,667149000,15196000,351127000,43483000,22147000,-3055000,-747000,-179000,6102000,-1038000,6281000,-53158000,155000,-58668000,2419000,-7956000,-23000,8305000,-747000,583247000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Insmed, Inc.",False,False,NMS,29.13,1630526402,1.0899982,28.32,29.13,28.13,1003452,PRE,0,2,3.8872976,28.13 - 29.13,28.04,0.0,0.0,18,13,finmb_29978,Insmed Incorporated,NasdaqGS,USD,777817,689285,7.129999,0.32409087,22.0 - 45.44,-16.31,-0.35893485,22.0,45.44,1620304200,1635337800,1635769800,-3.165,-2.58,-3.56,-8.182584,1.952,25.024,4.105999,0.16408244,30.25913,-1.1291313,-0.03731539,3349716736,-11.290698,14.923155,15,America/New_York,EDT,-14400000,2.26,,,45.44,22.0,25.02,30.26,777.82k,689.28k,114.99M,,97.34M,1.32%,95.70%,8.11M,10.86,8.88%,7.05%,8.16M,,,,,,0.00%,,,1:10,"Mar 02, 2011","Dec 30, 2020","Mar 30, 2021",-190.36%,-172.09%,-26.36%,-156.42%,167.77M,1.66,9.10%,33.86M,-279.5M,-319.37M,-3.16,,409.75M,3.96,407.6M,202.15,6.16,1.95,-289.69M,-143.26M,Value,08807-1704,Healthcare,521,6,3,"Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",Bridgewater,908 977 9900,NJ,9,1609372800,1625097600,3,United States,http://www.insmed.com,86400,6,700 US Highway 202/206,Biotechnology
t-3,INSM,403847000,114992000,21814000,,-61426000,,-61854000,49663000,18611000,-54114000,-54114000,,-7469000,,,,428000,42495000,96609000,23884000,-7312000,,-61854000,-61854000,1471000,2069119000,480047000,405318000,49714000,201000,885365000,1014000,-1664717000,11338000,-98000,73319000,641911000,78754000,-98000,103263000,707312000,15173000,346001000,35473000,25005000,8006000,-1881000,-298000,250756000,-1900000,251054000,212969000,47000,-35953000,2664000,-4828000,1981000,13704000,-1881000,628558000,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,us_market,"Insmed, Inc.",False,False,NMS,29.13,1630526402,1.0899982,28.32,29.13,28.13,1003452,PRE,0,2,3.8872976,28.13 - 29.13,28.04,0.0,0.0,18,13,finmb_29978,Insmed Incorporated,NasdaqGS,USD,777817,689285,7.129999,0.32409087,22.0 - 45.44,-16.31,-0.35893485,22.0,45.44,1620304200,1635337800,1635769800,-3.165,-2.58,-3.56,-8.182584,1.952,25.024,4.105999,0.16408244,30.25913,-1.1291313,-0.03731539,3349716736,-11.290698,14.923155,15,America/New_York,EDT,-14400000,2.26,,,45.44,22.0,25.02,30.26,777.82k,689.28k,114.99M,,97.34M,1.32%,95.70%,8.11M,10.86,8.88%,7.05%,8.16M,,,,,,0.00%,,,1:10,"Mar 02, 2011","Dec 30, 2020","Mar 30, 2021",-190.36%,-172.09%,-26.36%,-156.42%,167.77M,1.66,9.10%,33.86M,-279.5M,-319.37M,-3.16,,409.75M,3.96,407.6M,202.15,6.16,1.95,-289.69M,-143.26M,Value,08807-1704,Healthcare,521,6,3,"Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.",Bridgewater,908 977 9900,NJ,9,1609372800,1625097600,3,United States,http://www.insmed.com,86400,6,700 US Highway 202/206,Biotechnology
